Table 3:

Study Objectives and Outcomes

OBJECTIVES	OUTCOME MEASUREMENTS
Primary
1. Impact of the intervention on HTN medication adherence at 12 months 2. Impact of the intervention on DM medication adherence at 12 months 3. Impact of the intervention on Lipid medication adherence at 12 months 4. Impact of the intervention on SBP control at 12 months 5. Impact of the intervention on A1C control at 12 months	1. Achievement of PDC ≥80% for at least one antihypertensive medication in each currently prescribed BP medication class at 12 months following the index office visit 2. Achievement of PDC≥80% for at least one medication in each currently prescribed non-insulin glycemic medication class at 12 months following the index office visit 3. Achievement of a PDC ≥80% for a statin medication if currently prescribed at 12 months following the index office visit 4. Differential change in SBP from the index SBP to last SBP in the 12-month period following the index office visit 5. Differential change in A1C value from the index A1C to last A1C in the 12-month period following the index office visit
Secondary
1. Impact of the intervention on overall healthcare costs 2. Predicted long-term health impact and cost-effectiveness of the intervention from the health system (payer) perspective	1. Measure the incremental medical care costs attributable to the eCDC-CDS intervention, defined from the health system perspective, measured using utilization incurred in the 12-month pre- and post-index date periods. 2. If the primary endpoints show effectiveness, we will use a cardiovascular disease microsimulation model to predict the long-term impact of the eCDC-CDS intervention on health outcomes and its cost-effectiveness, defined from the health system perspective, over up to a 30-year prospective time horizon.
Exploratory
1, 2, 3. Impact of the intervention on medication adherence for HTN medication, DM medication and lipid medication at 18 months 4. Impact of the intervention on SBP control at 18 months 5. Impact of the intervention on A1C control at 18 months	1, 2, 3. Adherence endpoints as described above for primary objectives at 18 months following the index office visit for antihypertensive, glucose lowering, and statin medications 4. Reduction in SBP from the index SBP to last SBP in the 18-month period following the index office visit 5. Reduction in A1C value from the index A1C to last A1C in the 18-month period following the index office visit
6, 7. Impact of the intervention on DBP control at 12 and 18 months 8, 9. Impact of the intervention on LDL control at 12 and 18 months	6, 7. Reduction in DBP from the index DBP to last DBP in the 12-month period (6) and 18-month period (7) following the index office visit 8, 9. Reduction in LDL value from the index LDL to last LDL in the 12-month period (8) and 18-month period (9) following the index office visit